Kellik Tarihe mi Karışıyor? %539 BAŞARI, Hormon Riski Yok!

In this video, we delve into the results of the latest Phase 3 clinical trials of Clascoterone (5% topical solution). In these massive studies conducted on 1,465 patients in America and Europe, we explain, with supporting evidence, why this new agent fighting hair loss is a "game changer." KEY ACHIEVEMENTS AND DETAILS: 1. Unique Mechanism: Instead of systemically suppressing Dihydrotestosterone (DHT) throughout the body, Clascoterone acts by binding locally directly to androgen receptors in the hair follicle. This significantly reduces the risk of hormonal side effects (such as sexual dysfunction). 2. Efficacy: In one of two Phase 3 studies, a proportional improvement of up to 539% in hair count in the target area was observed compared to placebo. This data is also supported by patients' perceived hair growth (Patient-Reported Outcomes - PROs). 3. Safety: The rates of treatment-related adverse events (TEEs) are similar in the active treatment group to the placebo (carrier cream) group. This indicates that the tolerability of the treatment is very high. 4. When is it coming? Cosmo Pharmaceuticals plans to complete the necessary 12-month safety data in Spring 2026, followed by simultaneous regulatory applications for the US (FDA) and European (EMA) markets. Don't forget to subscribe to my channel and share the video with a friend ✌🏿 #Klaskoteron #Breezula #HairLoss #DHTEprevention #AGA #FinasterideAlternative #BaldnessTreatment #30YearsOfInnovation